Table 1.
Model input parameters for estimation of costs and effects related to MammaPrint® and endocrine therapy: Information about the characteristics of the patient population simulated in this study
| Parameter | Value | SE | Alpha | Beta | Source |
|---|---|---|---|---|---|
| Mean age (years) | 63.3 | n.v. | n.a. | n.a. | Netherlands Cancer Registry (national data) [14] |
| Premenopausal (%) | 18 | 0.003 | 5257 | 23,351 | Netherlands Cancer Registry (proportions based on national data) [14] |
| Postmenopausal (%) | 82 | 23,351 | 5257 | ||
| Adjuvant endocrine treatment | [24] | ||||
| 5 years of AI (%) | 74 | 0.012 | 380 | 1071 | |
| 2.5 years of tamoxifen followed by 2.5 years AI (%) | 26 | 1071 | 380 | ||
| Employed (%) | 53 | 0.001 | 300,289 | 270,602 | Statistics Netherlands [42] |
AI aromatase inhibitor, n.a. not applicable, n.v. not varied, SE standard error